secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001493152-25-003916
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.02, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M
--------------------------------------------------------------------------

- Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.
- Preliminary unaudited cash balance at Dec 31, 2024: approximately $9.6 million.
- Q4'24 capital: $9.5M from public offerings, $2.0M from warrants, $3.1M from ATM; additional $4.25M in Jan 2025.
- CEO states termination removes potential stock overhang, supports shareholder value.
- IND cleared for CLD-101 Phase 1b/2 trial for high-grade glioma; enrollment to start Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225003916/0001493152-25-003916-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225003916/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003916

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer